Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma Group (MREO) Other Working Capital Changes: 2023-2025

Historic Other Working Capital Changes for Mereo BioPharma Group (MREO) over the last 3 years, with Sep 2025 value amounting to -$188,000.

  • Mereo BioPharma Group's Other Working Capital Changes rose 78.39% to -$188,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.0 million, marking a year-over-year decrease of 720.00%. This contributed to the annual value of -$3.0 million for FY2024, which is 415.57% down from last year.
  • Per Mereo BioPharma Group's latest filing, its Other Working Capital Changes stood at -$188,000 for Q3 2025, which was up 70.11% from -$629,000 recorded in Q2 2025.
  • Mereo BioPharma Group's Other Working Capital Changes' 5-year high stood at $9.4 million during Q2 2023, with a 5-year trough of -$8.5 million in Q3 2023.
  • Its 3-year average for Other Working Capital Changes is -$373,364, with a median of -$629,000 in 2025.
  • Its Other Working Capital Changes has fluctuated over the past 5 years, first tumbled by 179.72% in 2024, then surged by 113.82% in 2025.
  • Mereo BioPharma Group's Other Working Capital Changes (Quarterly) stood at $1.8 million in 2023, then plummeted by 179.72% to -$1.5 million in 2024, then soared by 78.39% to -$188,000 in 2025.
  • Its last three reported values are -$188,000 in Q3 2025, -$629,000 for Q2 2025, and $268,000 during Q1 2025.